AU695488B2 - Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation - Google Patents

Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation

Info

Publication number
AU695488B2
AU695488B2 AU19510/95A AU1951095A AU695488B2 AU 695488 B2 AU695488 B2 AU 695488B2 AU 19510/95 A AU19510/95 A AU 19510/95A AU 1951095 A AU1951095 A AU 1951095A AU 695488 B2 AU695488 B2 AU 695488B2
Authority
AU
Australia
Prior art keywords
xanthine
reactivity
preparation
reducing
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19510/95A
Other versions
AU1951095A (en
Inventor
Hiristo Anagnostopulos
Ulrich Gebert
Alexander Kapp
Claus Kroegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU1951095A publication Critical patent/AU1951095A/en
Application granted granted Critical
Publication of AU695488B2 publication Critical patent/AU695488B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU19510/95A 1994-04-05 1995-03-21 Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation Ceased AU695488B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4411660A DE4411660A1 (en) 1994-04-05 1994-04-05 Use of xanthine derivatives to reduce the pathological hyperreactivity of eosinophilic granulocytes, new xanthine compounds and processes for their preparation
DE4411660 1994-04-05
PCT/EP1995/001060 WO1995026727A1 (en) 1994-04-05 1995-03-21 Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them

Publications (2)

Publication Number Publication Date
AU1951095A AU1951095A (en) 1995-10-23
AU695488B2 true AU695488B2 (en) 1998-08-13

Family

ID=6514636

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19510/95A Ceased AU695488B2 (en) 1994-04-05 1995-03-21 Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation

Country Status (11)

Country Link
EP (1) EP0758239A1 (en)
JP (1) JPH09510983A (en)
KR (1) KR100373948B1 (en)
CN (1) CN1098686C (en)
AU (1) AU695488B2 (en)
CA (1) CA2187081A1 (en)
DE (1) DE4411660A1 (en)
HU (1) HUT74732A (en)
RU (1) RU2159617C2 (en)
UA (1) UA39136C2 (en)
WO (1) WO1995026727A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO1999049865A1 (en) * 1998-03-31 1999-10-07 Mayo Foundation For Medical Education And Research Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
JP2005529934A (en) 2002-05-31 2005-10-06 シェーリング　コーポレイション Process for preparing xanthine phosphodiesterase V inhibitor and precursors thereof
SI1509525T1 (en) * 2002-05-31 2006-12-31 Schering Corp Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0413278A2 (en) * 1989-08-16 1991-02-20 Hoechst Japan Limited Use of xanthine derivatives against peptic ulcers
AU5671294A (en) * 1992-11-16 1994-06-08 Cell Therapeutics, Inc. Hydroxyl-containing compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918297D0 (en) * 1989-08-10 1989-09-20 Beecham Group Plc Novel treatment
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
WO1993003728A1 (en) * 1991-08-27 1993-03-04 Temple University Of The Commonwealth System Of Xanthine suppression of antigen activation of t- or b-cells
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Compositions for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0413278A2 (en) * 1989-08-16 1991-02-20 Hoechst Japan Limited Use of xanthine derivatives against peptic ulcers
AU5671294A (en) * 1992-11-16 1994-06-08 Cell Therapeutics, Inc. Hydroxyl-containing compounds

Also Published As

Publication number Publication date
EP0758239A1 (en) 1997-02-19
KR970702044A (en) 1997-05-13
RU2159617C2 (en) 2000-11-27
UA39136C2 (en) 2001-06-15
DE4411660A1 (en) 1995-10-12
HU9602712D0 (en) 1996-11-28
JPH09510983A (en) 1997-11-04
CN1098686C (en) 2003-01-15
KR100373948B1 (en) 2003-06-09
AU1951095A (en) 1995-10-23
CA2187081A1 (en) 1995-10-12
WO1995026727A1 (en) 1995-10-12
CN1145029A (en) 1997-03-12
HUT74732A (en) 1997-02-28

Similar Documents

Publication Publication Date Title
EP0679695A3 (en) Processes for the preparation of hydroxygallium phthalocyanine
AU4525396A (en) Process for the preparation of perfluorocarbons
EP0699695A3 (en) Process for the preparation of copolyacetals
AU2734895A (en) Process for the preparation of 3-aryluracils
AU666087B2 (en) Method for the preparation of polysaccharide derivatives
AU1407895A (en) Preparation of dehydroxylated supports
AU2762395A (en) Process for the preparation of azanoradamantane benzamides
AU1230595A (en) Process for the preparation of polyalkyl-1-oxa- diazaspirodecane compounds
AU4311696A (en) Process for the preparation of lamotrigine
AU8799491A (en) Process for the preparation of diethers
AU5194798A (en) Process for the preparation of radiopharmaceuticals
GB9509826D0 (en) Process for the preparation of imidazolutidine
AU695488B2 (en) Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation
AU2173597A (en) Process for the preparation of tenidap
AU7696394A (en) Process for the preparation of alkylglycosides
AU2970989A (en) Process for the preparation of urea
AU8251891A (en) Process for the preparation of 1-alkylisoquinoline derivatives
AU8036291A (en) Process for the preparation of 1-hydroxymethylpyrazoles
AU2464297A (en) Process and intermediate compounds for the preparation of pesticidal fluoroolefin compounds
AU5151093A (en) Process for the preparation of alkylglycosides
AU3783097A (en) Process for the preparation of hexanitrohexaazaisowurtzitanes
AU5067590A (en) New bronchospasmolytic compounds and process for their preparation
AU9139591A (en) Process for the preparation of bromonitro-alcohols, dibromonitro-alcohols and blends thereof
PL320799A1 (en) 14alpha, 17alpha-c2-bridged derivatives of 19-norprogesterone
AU3346495A (en) Process for the preparation of oligosaccharide mixtures

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired